Escherichia coli Infections

Infections with bacteria of the species ESCHERICHIA COLI.

Also Known As:

E coli Infections; E. coli Infection; Infections, E coli; Infections, Escherichia coli; E coli Infection; E. coli Infections; Escherichia coli Infection; Infection, E coli; Infection, E. coli; Infection, Escherichia coli

Networked: 524 relevant articles (39 outcomes, 43 trials/studies)

Relationship Network

Disease Context: Research Results

Infections: 526564
- Bacterial Infections and Mycoses: 1
  - Bacterial Infections: 24368
    - Gram-Negative Bacterial Infections: 918
      - Enterobacteriaceae Infections: 141
        Escherichia coli Infections: 524
        Escherichia coli Meningitis: 82

Related Diseases

1.	Infections
2.	Abdominal Abscess
3.	Sepsis (Septicemia)
4.	Inflammation (Inflammations)
5.	Body Weight (Weight, Body)

Experts

1.	Yoshikai, Yasunobu: 5 articles (01/2021 - 09/2003)
2.	Kinoshita, Manabu: 4 articles (09/2013 - 08/2004)
3.	Seki, Shuhji: 4 articles (09/2013 - 08/2004)
4.	Boerman, Otto C: 4 articles (11/2007 - 07/2002)
5.	Zhang, Jian: 3 articles (04/2022 - 01/2021)
6.	Liu, Yusen: 3 articles (01/2022 - 12/2009)
7.	Nelin, Leif D: 3 articles (01/2022 - 12/2009)
8.	Ibarra, Cristina: 3 articles (01/2021 - 01/2016)
9.	Gomis, Susantha: 3 articles (01/2020 - 02/2003)
10.	Willson, Philip: 3 articles (01/2020 - 02/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Escherichia coli Infections:

1.	Peptides (Polypeptides)IBA 01/01/2019 - "Of these peptides, 16 with seven repeat units had the highest average selectivity index (GMSI = 99.07) for all of the Gram-negative bacteria tested and remained highly effective in combating Escherichia coli infection in vivo. " 10/01/2012 - "A lethal Escherichia coli infection model was established and the efficacy of Onc72 was evaluated for different peptide doses considering the survival rates of each dose group and the bacterial counts in blood, lavage and organs. " 01/01/2023 - "Bioinformatics analysis showed these differentially expressed peptides might be associated with "MHC class I protein binding" and "pathogenic Escherichia coli infection" pathways, which might further affect the progression of AS. " 08/01/1997 - "Localization of radiolabeled chemotactic peptide at focal sites of Escherichia coli infection in rabbits: evidence for a receptor-specific mechanism." 11/01/1993 - "Localization of the peptides at sites of deep thigh Escherichia coli infection was determined by radioactivity measurements on excised tissues in rats (n = 6/time point) and rabbits as well as scintillation camera imaging in rabbits (n = 6). "
2.	Anti-Bacterial Agents (Antibiotics)IBA 12/16/2022 - "Surgery combined with antibiotics for thoracic vertebral Escherichia coli infection after acupuncture: A case report." 01/01/2022 - "Antibiotic-resistant Escherichia coli infection of poultry causes significant economic losses. " 01/01/2022 - "Multiplexed and Rapid AST for Escherichia coli Infection by Simultaneously Pyrosequencing Multiple Barcodes Each Specific to an Antibiotic Exposed to a Sample." 12/01/2021 - "Longitudinal antibiotic susceptibilities of neonatal Escherichia coli infection." 01/01/2021 - "These results provide necessary information for the development of antibiotic alternatives for the treatment of multidrug-resistant Escherichia coli infection."
3.	CytokinesIBA 09/01/2011 - "The objective of the present study was to determine the effect of dietary Gln supplementation on intestinal barrier function and intestinal cytokines in a model of Escherichia coli infection. " 01/01/2015 - "Proinflammatory cytokines measured in liver and spleen four days following an Escherichia coli infection revealed a potentiated proinflammatory response in liver, and to a lesser extent in spleen, in aged relative to young rats. " 08/15/2014 - "Th1 and Th17 cytokines were significantly elevated in Gram positive (Staphylococcus aureus and Streptococcus intermedius) and Th2 cytokine (IL-10) in Gram negative (Bacteroides fragilis and Escherichia coli) infections (p<0.05). " 08/15/2014 - "TRIL is involved in cytokine production in the brain following Escherichia coli infection." 08/01/1997 - "Cytokines in haemolytic uraemic syndrome associated with verocytotoxin-producing Escherichia coli infection."
4.	Spectinomycin (Spectinomycin Hydrochloride)FDA Link 07/01/1993 - "Effect of spectinomycin on Escherichia coli infection in 1-day-old ducklings." 07/01/1988 - "Therapeutic efficacy of medicating drinking water with spectinomycin and lincomycin-spectinomycin in experimental Escherichia coli infection in poultry." 03/01/1977 - "Three replicate trials were conducted with broiler male chicks to test the therapeutic efficacy of doxycycline, chlortetracycline and lincomycin-spectinomycin in water against an artifically induced Escherichia coli infection. "
5.	Lincomycin (Lincocin)FDA Link 07/01/1988 - "Therapeutic efficacy of medicating drinking water with spectinomycin and lincomycin-spectinomycin in experimental Escherichia coli infection in poultry." 03/01/1977 - "Three replicate trials were conducted with broiler male chicks to test the therapeutic efficacy of doxycycline, chlortetracycline and lincomycin-spectinomycin in water against an artifically induced Escherichia coli infection. "
6.	Doxycycline (Periostat)FDA LinkGeneric 01/01/1988 - "Therapeutic efficacy of doxycycline hyclate in experimental Escherichia coli infection in broilers." 03/01/1977 - "Three replicate trials were conducted with broiler male chicks to test the therapeutic efficacy of doxycycline, chlortetracycline and lincomycin-spectinomycin in water against an artifically induced Escherichia coli infection. "
7.	AntigensIBA 08/24/2023 - "Correction: Quinn et al. GlnH, a Novel Antigen That Offers Partial Protection against Verocytotoxigenic Escherichia coli Infection. " 01/13/2023 - "GlnH, a Novel Antigen That Offers Partial Protection against Verocytotoxigenic Escherichia coli Infection." 01/01/2022 - "The results above demonstrate that immunization of Escherichia coli CE9 ghosts via intramuscular injection elicits a more robust antigen-specific immune response in mice to prevent the Escherichia coli infection." 06/01/2000 - "Effects of dietary vitamin E on responses to SRBC antigens and Escherichia coli infection were studied in chicks from White Leghorn lines selected for 24 generations for high (HAS) and low (LAS) antibody responses to SRBC. " 03/01/1995 - "The presence of capsular antigens, mainly the K1 capsular polysaccharide, has been associated with invasiveness in E coli infections. "
8.	Trimethoprim (Proloprim)FDA LinkGeneric 07/01/1984 - "Some pharmacokinetic aspects of four sulphonamides and trimethoprim, and their therapeutic efficacy in experimental Escherichia coli infection in poultry." 05/01/1994 - "Whilst the cure rate for Escherichia coli infection was similar, 81.5% cured with nitrofurantoin MR, 82.5% with co-trimoxazole and 78.4% by trimethoprim, for non-E. " 01/01/2021 - "The antibiotic trimethoprim (TMP) is used to treat a variety of Escherichia coli infections, but its efficacy is limited by the rapid emergence of TMP-resistant bacteria. "
9.	Ampicillin (Omnipen)FDA LinkGeneric 01/01/1981 - "Some pharmacokinetical aspects of ampicillin trihydrate and its therapeutic efficacy in experimental Escherichia coli infection in poultry." 10/01/2002 - "The proportion of E coli infections that were resistant to ampicillin increased significantly among preterm infants from 29% (2 of 7) in 1998 to 84% (16 of 18) in 2000 but not in full-term infants: 50% (4 of 8) in 1998 and 25% (1 of 4) in 2000. " 11/01/2001 - "There was an increase in the proportion of Escherichia coli infections that were ampicillin resistant between 1996 and 1998, but the proportion decreased. " 01/01/2000 - "Ninety-one percent of infants who developed ampicillin-resistant E coli infections were preterm, and 59% of these infants were born to mothers who had received IAP. " 01/01/2000 - "No deaths occurred among susceptible E coli infections, whereas 41% of ampicillin-resistant E coli infections were fatal. "
10.	Interleukin-6 (Interleukin 6)IBA 05/01/1992 - "The present study examined the influence of the mouse Lps genotype on the interleukin-6 (IL-6) and polymorphonuclear leucocyte (PMN) responses to mucosal Escherichia coli infection. " 08/01/1996 - "Interleukin-6 is required for a protective immune response to systemic Escherichia coli infection." 02/01/1991 - "Il-6 is secreted in response to Escherichia coli infection of the urinary tract. " 01/01/2021 - "We have previously shown that Mkp-1-deficient mice produce elevated TNF-α, IL-6, and IL-10 following systemic Escherichia coli infection, and they exhibited increased mortality, elevated bacterial burden, and profound metabolic alterations. " 08/01/1996 - "We have used IL-6-deficient mice to investigate the role of IL-6 during virulent Escherichia coli infection and in lipopolysaccharide (LPS)-induced mortality. "

Therapies and Procedures

1.	Therapeutics 06/01/1992 - "The two regimens are equally effective for E coli infection, but single-dose therapy is ineffective for S saprophyticus." 01/01/2023 - "Characterization of a lytic Escherichia coli phage CE1 and its potential use in therapy against avian pathogenic Escherichia coli infections." 01/25/2021 - "Special Issue: Pathogenic Escherichia coli: Infections and Therapies." 05/05/2020 - "(2) Methods: Since September 2015, eight patients with multi-drug resistant or especially recalcitrant Staphylococcus aureus, Enterococcus faecium, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli infections were treated with bacteriophage preparations as a therapy of last resort according to Article 37 of the Declaration of Helsinki. " 01/01/2020 - "Herein, this work aimed to investigate the changes of intestinal flora after PD or LVX therapy of Escherichia coli infection in rats. "
2.	Intravenous Administration 01/01/1994 - "Intravenous administration of several magainin analogues has been shown to treat effectively systemic Escherichia coli infections in the mouse." 12/01/2005 - "In a mouse protection model, an advanced DAPT compound demonstrated efficacy against an Escherichia coli infection at a 50% protective dose of 2.4 mg/kg of body weight by single-dose intravenous administration."
3.	Cochlear Implantation 03/01/2013 - "To describe two cases of profound hearing loss secondary to enterohaemorrhagic Escherichia coli infection, and to report the efficacy of subsequent cochlear implantation. "
4.	Transplantation 05/01/2002 - "Biliary leakage in the early period after the transplantation was controlled by drainage, and E.coli infection was effectively treated with antibiotics. "
5.	Oral Administration 01/01/1989 - "In this study, the effect of oral administration of CVE against Escherichia coli infection was examined. " 04/01/2007 - "Prevention of pathogenic Escherichia coli infection in mice and stimulation of macrophage activation in rats by an oral administration of probiotic Lactobacillus casei I-5." 07/01/2002 - "Enhancement of chicken resistance against Escherichia coli infection by oral administration of Bifidobacterium thermophilum preparations." 01/01/1990 - "The effects of oral administration of a hot water extract of Chlorella vulgaris (CVE) on the restoration of the leukocyte number and on the resistance against Escherichia coli infection were examined in cyclophosphamide (CY)-treated rats. " 10/18/2023 - "Oral administration of a 2-aminopyrimidine robenidine analogue (NCL195) significantly reduces Staphylococcus aureus infection and reduces Escherichia coli infection in combination with sub-inhibitory colistin concentrations in a bioluminescent mouse model."